Systemic therapy of atopic dermatitis

Clinical and Experimental Dermatology

Volumn 25, Issue 7, 2000, Pages 559-566

  Sidbury, R ^a,b   Hanifin, J M ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID; OPIATE ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; PREDNISONE; PRIMROSE OIL; PSORALEN; TACROLIMUS;

ATOPIC DERMATITIS; BONE MARROW CELL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; MAINTENANCE THERAPY; PRIORITY JOURNAL; PUVA; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

ANTI-ALLERGIC AGENTS; ANTI-BACTERIAL AGENTS; DERMATITIS, ATOPIC; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; LEUKOTRIENES; MEDICINE, CHINESE TRADITIONAL; NARCOTICS; PHOSPHODIESTERASE INHIBITORS; PLANT EXTRACTS;

EID: 0034489868     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00697.x     Document Type: Review

References (58)

1. Personal communication
2. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation
3. Diagnosis and treatment of atopic dermatitis. Management of atopic dermatitis: Current status and future possibilities
4. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis
5. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions
6. 2 regulation of cytokine production in atopic dermatitis
7. Efficacy of low-dose cyclosporin in severe atopic disease
8. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro II: Inhibition of the production of IL-2 and interferon-gamma, but not B cell-stimulating factor 2
9. Influence of FK506 on T lymphocytes. Langerhans cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: A preliminary study
10. Antipruritic effect of oral cyclosporin A in atopic dermatitis
11. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
12. Cyclosporin A in severe, therapy-resistant atopic dermatitis: Report of an international workshop, April 1993
13. Cyclosporin in children with severe atopic dermatitis
14. Cyclosporin in atopic dermatitis: Time to relapse and effect of intermittent therapy
15. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
16. Tacrolimus: The drug for the turn of the millennium?
17. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chornic plaque psoriasis
18. Pitryiasis rubra pilaris - Prolonged treatment with methotrexate
19. Immunosuppressive agents in dermatology
20. Azathioprine in dermatology: A survey of current practice in the United Kingdom
21. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatology patients
22. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses
23. Mycophenolate mofetil in autoimmune and inflammatory skin disorders
24. Dyshidrotic eczema treated with mycophenolate mofetil
25. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients
26. Mycophenolic acid for psoriasis: A review of pharmacology, long-term efficacy, and safety
27. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels
28. Long-term therapy with recombinant interferon-gamma (rIFN-g) for atopic dermatitis
29. High dose gamma globulin treatment for atopic dermatitis
30. High dose intravenous immunoglobulin in atopic dermatitis and hyper IgE syndrome
31. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy resistant atopic dermatitis
32. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
33. Adverse effects of intravenous immunoglobulin therapy
34. The role of antihistamines in atopic dermatitis
35. Mechanism of action of antipruritic drugs
36. A double-blind trial of H1 and H2 receptor anatagonists in the treatment of atopic dermatitis
37. Ketotifen treatment of atopic dermatitis in childhood
38. Do mast cells play a role in atopic dermatitis?
39. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis
40. Immunopharmacologic aspects of atopic dermatitis
41. Heterologous desensitization of leukocytes: A possible mechanism of beta adrenergic blockade in atopic dermatitis
42. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness
43. Theophylline ethylenediamine as an antipruritic agent
44. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: Tachyphylaxis after theophylline therapy
45. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
46. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
47. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodicsterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
48. Staphylococcal infections in patients with atopic dermatitis
49. Specific C-receptors for itching in human skin
50. Butorphanol-induced pruritus antagonized by naloxone
51. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases
52. The leukotiene antagonist zafirlukast as a therapeutic agent for atopic dermatitis
53. Diet, nutrition, and allergy in atopic dermatitis
54. Epogam evening primrose oil treatment in atopic dermatitis and asthma
55. One year follow-up of children treated with Chinese medicinal herbs for atopic eczema
56. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis
57. Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczelna
58. Traditional Chinese medicine for the treatment of dermatologic disorders